• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

US FluView - Weekly Surveillance Flu report 2021/2022 season - for trend analysis

Weekly U.S. Influenza Surveillance Report


Updated August 19, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 32, ending August 13, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested41,6573,385,846
No. of positive specimens (%)165 (0.4%)134,111 (4.0%)
Positive specimens by type
Influenza A147 (89.1%)131,975 (98.4%)
Influenza B18 (10.9%)2,136 (1.6%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested11,9251,019,489
No. of positive specimens2725,565
Positive specimens by type/subtype
Influenza A25 (92.6%)25,421 (99.4%)
(H1N1)pdm09026 (0.1%)
H3N220 (100%)20,130 (99.9%)
H3N2v04 (<0.1%)
Subtyping not performed55,261
Influenza B2 (7.4%)144 (0.6%)
Yamagata lineage01 (2.4%)
Victoria lineage040 (97.6%)
Lineage not performed2103




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Novel Influenza A Virus


A human infection with a novel influenza A virus was reported by the Oregon Health Authority. The patient was infected with an influenza A(H1N2) variant (A(H1N2)v) virus. The patients is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials did not identify contact with swine or agricultural fair attendance by the patient prior to illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person spread of this virus has been confirmed to date associated with this case. This is the first patient infected with an H1N2v virus reported in the United States in 2022.

A total of four human infections with a variant influenza A virus have been reported in the United States in 2022, including three H3N2v (West Virginia) and one H1N2v (Oregon).

When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following close proximity to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm. Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 32, 1.4% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 32, the percentage of visits for respiratory illness reported in ILINet was 5.9% among those 0-4 years, 2.0% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.7% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 32
(Week ending
Aug. 13, 2022)
Week 31
(Week ending
Aug. 6, 2022)
Week 32
(Week ending
Aug. 13, 2022)
Week 31
(Week ending
Aug. 6, 2022)
Very High0011
High0054
Moderate011410
Low313554
Minimal5153581588
Insufficient Data10293272




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 32, 39 (0.3%) of 14,576 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 32, 457 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on August 18, 2022, 9.9% of the deaths that occurred during the week ending August 13, 2022 (week 32), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,165 PIC deaths reported for this week, 1,192 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and six listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 32.

A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Weekly U.S. Influenza Surveillance Report


Updated August 26, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 33, ending August 20, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested32,4913,431,123
No. of positive specimens (%)159 (0.5%)134,375 (3.9%)
Positive specimens by type
Influenza A136 (85.5%)132,205 (98.4%)
Influenza B23 (14.5%)2,170 (1.6%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested11,0621,059,682
No. of positive specimens3925,703
Positive specimens by type/subtype
Influenza A37 (94.9%)25,557 (99.4%)
(H1N1)pdm091 (3.4%)28 (0.1%)
H3N228 (96.6%)20,237 (99.9%)
H3N2v04 (<0.1%)
Subtyping not performed85,288
Influenza B2 (5.1%)146 (0.6%)
Yamagata lineage01 (2.4%)
Victoria lineage1 (100%)41 (97.6%)
Lineage not performed1104




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Novel Influenza A Virus


A human infection with a novel influenza A virus was reported by the Ohio Department of Health. The patient was infected with a swine-origin influenza A(H1N2) variant (A(H1N2)v) virus. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had attended an agricultural fair on the day of their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified. This is the second patient infected with an H1N2v virus reported in the United States in 2022.

A total of five human infections with variant influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and two H1N2v (Ohio, Oregon) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 33, 1.5% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 33, the percentage of visits for respiratory illness reported in ILINet was 6.3% among those 0-4 years, 2.4% among those 5-24 years, 1.0% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 33
(Week ending
Aug. 20, 2022)
Week 32
(Week ending
Aug. 13, 2022)
Week 33
(Week ending
Aug. 20, 2022)
Week 32
(Week ending
Aug. 13, 2022)
Very High0012
High1065
Moderate202015
Low135636
Minimal5152568587
Insufficient Data00278284




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 33, 31 (0.2%) of 14,575 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 33, 477 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on August 25, 2022, 10.0% of the deaths that occurred during the week ending August 20, 2022 (week 33), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,320 PIC deaths reported for this week, 1,268 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and seven listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 33.

A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Weekly U.S. Influenza Surveillance Report


Updated September 2, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 34, ending August 27, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested41,3653,491,587
No. of positive specimens (%)209 (0.5%)134,683 (3.9%)
Positive specimens by type
Influenza A182 (87.1%)132,473 (98.4%)
Influenza B27 (12.9%)2,210 (1.6%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested10,8051,071,312
No. of positive specimens4025,775
Positive specimens by type/subtype
Influenza A39 (97.5%)25,628 (99.4%)
(H1N1)pdm095 (17.9%)39 (0.2%)
H3N223 (82.1%)20,307 (99.8%)
H3N2v04 (<0.1%)
Subtyping not performed115,278
Influenza B1 (2.5%)147 (0.6%)
Yamagata lineage01 (2.3%)
Victoria lineage1 (100%)42 (97.7%)
Lineage not performed0104




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 34, 1.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 34, the percentage of visits for respiratory illness reported in ILINet was 7.0% among those 0-4 years, 2.9% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 34
(Week ending
Aug. 27, 2022)
Week 33
(Week ending
Aug. 20, 2022)
Week 34
(Week ending
Aug. 27, 2022)
Week 33
(Week ending
Aug. 20, 2022)
Very High0032
High11106
Moderate311821
Low227456
Minimal4751537574
Insufficient Data20287270




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 34, 28 (0.2%) of 14,510 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 34, 486 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on September 1, 2022, 9.2% of the deaths that occurred during the week ending August 27, 2022 (week 34), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,117 PIC deaths reported for this week, 1,120 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and eight listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 34. The death was associated with an influenza A virus for which no subtyping was performed and occurred during week 29 (the week ending July 23, 2022).

A total of 34 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Weekly U.S. Influenza Surveillance Report


Updated September 9, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 35, ending September 3, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested42,2613,547,791
No. of positive specimens (%)247 (0.6%)135,046 (3.8%)
Positive specimens by type
Influenza A228 (92.3%)132,809 (98.3%)
Influenza B19 (7.7%)2,237 (1.7%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested10,1061,082,187
No. of positive specimens1825,893
Positive specimens by type/subtype
Influenza A15 (83.3%)25,743 (99.4%)
(H1N1)pdm094 (50.0%)46 (0.2%)
H3N24 (50.0%)20,385 (99.8%)
H3N2v04 (<0.1%)
Subtyping not performed75,308
Influenza B3 (16.7%)150 (0.6%)
Yamagata lineage01 (2.3%)
Victoria lineage042 (97.7%)
Lineage not performed3107




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 35, 1.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 35, the percentage of visits for respiratory illness reported in ILINet was 7.2% among those 0-4 years, 3.0% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 35
(Week ending
Sep. 3, 2022)
Week 34
(Week ending
Aug. 27, 2022)
Week 35
(Week ending
Sep. 3, 2022)
Week 34
(Week ending
Aug. 27, 2022)
Very High0034
High31810
Moderate232520
Low226074
Minimal4548524542
Insufficient Data31309279




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 35, 28 (0.2%) of 14,481 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 35, 509 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on September 8, 2022, 9.6% of the deaths that occurred during the week ending September 3, 2022 (week 35), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 1,769 PIC deaths reported for this week, 963 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and seven listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


No influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 35.

A total of 34 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Weekly U.S. Influenza Surveillance Report


Updated September 16, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 36, ending September 10, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested40,6983,612,434
No. of positive specimens (%)279 (0.7%)135,450 (3.7%)
Positive specimens by type
Influenza A263 (94.3%)133,178 (98.3%)
Influenza B16 (5.7%)2,272 (1.7%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested10,1451,093,878
No. of positive specimens3825,990
Positive specimens by type/subtype
Influenza A38 (100%)25,839 (99.4%)
(H1N1)pdm094 (14.8%)56 (0.3%)
H3N223 (85.2%)20,464 (99.7%)
H3N2v04 (<0.1%)
Subtyping not performed115,315
Influenza B0 (0%)151 (0.6%)
Yamagata lineage01 (2.3%)
Victoria lineage043 (97.7%)
Lineage not performed0107




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Novel Influenza A Virus


Two human infections with a novel influenza A virus were reported during week 36 (Michigan and Wisconsin). Both patients were infected with influenza A(H1N2) variant (A(H1N2)v) viruses.

The Michigan Department of Health and Human Services reported one infection in a patient <18 years of age. The patient was not hospitalized and has recovered from their illness. An investigation by local public health officials found that the patient had attended an agricultural fair prior to their illness onset. Additional investigation identified one household contact who had respiratory illness. This contact attended the same agricultural fair and became ill at the same time as the patient. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified.

The Wisconsin Department of Health reported one infection in a patient < 18 years of age. An investigation by local public health officials is ongoing.

A total of seven human infections with variant novel influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and four H1N2v (Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person. Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 36, 1.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 36, the percentage of visits for respiratory illness reported in ILINet was 7.8% among those 0-4 years, 3.1% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 36

(Week ending
Sep. 10, 2022)
Week 35

(Week ending
Sep. 3, 2022)
Week 36

(Week ending
Sep. 10, 2022)
Week 35

(Week ending
Sep. 3, 2022)
Very High0045
High23610
Moderate323224
Low417065
Minimal4547528554
Insufficient Data12289271




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 36, 23 (0.2%) of 14,563 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 36, 577 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on September 15, 2022, 9.2% of the deaths that occurred during the week ending September 10, 2022 (week 36), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,055 PIC deaths reported for this week, 1,052 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and five listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 36. The death was associated with an influenza A(H3) virus and occurred during week 20 (the week ending May 21, 2022).

A total of 35 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Weekly U.S. Influenza Surveillance Report


Updated September 23, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 37, ending September 17, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested47,5463,676,988
No. of positive specimens (%)378 (0.8%)135,983 (3.7%)
Positive specimens by type
Influenza A353 (93.4%)133,676 (98.3%)
Influenza B25 (6.6%)2,307 (1.7%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested10,4361,104,730
No. of positive specimens3526,062
Positive specimens by type/subtype
Influenza A31 (88.6%)25,907 (99.4%)
(H1N1)pdm092 (9.1%)62 (0.3%)
H3N220 (90.9%)20,517 (99.7%)
H3N2v04 (<0.1%)
Subtyping not performed95,324
Influenza B4 (11.4%)155 (0.6%)
Yamagata lineage01 (2.3%)
Victoria lineage043 (97.7%)
Lineage not performed4111




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Novel Influenza A Virus


A human infection with a novel influenza A virus was reported by the Georgia Department of Public Health. The patient was infected with an influenza A(H1N2) variant (A(H1N2)v) virus. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had swine contact and had attended agricultural fairs prior to their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified.

A total of eight human infections with variant novel influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and five H1N2v (Georgia, Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 37, 2.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 37, the percentage of visits for respiratory illness reported in ILINet was 8.1% among those 0-4 years, 3.2% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 37
(Week ending
Sep. 17, 2022)
Week 36
(Week ending
Sep. 10, 2022)
Week 37
(Week ending
Sep. 17, 2022)
Week 36
(Week ending
Sep. 10, 2022)
Very High1035
High1296
Moderate332432
Low347172
Minimal4746546545
Insufficient Data00276269




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 37, 32 (0.2%) of 14,515 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 37, 637 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on September 22, 2022, 9.2% of the deaths that occurred during the week ending September 17, 2022 (week 37), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.6% for this week. Among the 2,058 PIC deaths reported for this week, 1,055 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and four listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


Two influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 37. One death was associated with an influenza B virus with no lineage determined and occurred during week 15 (the week ending April 16, 2022). The other death was associated with an influenza A(H3) virus and occurred during week 21 (the week ending May 28, 2022).

A total of 37 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Weekly U.S. Influenza Surveillance Report

Print
Updated September 30, 2022
fluview-banner2.jpg

2021-2022 Influenza Season for Week 38, ending September 24, 2022

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. Virologic Surveillance

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

No. of specimens tested50,2923,743,239
No. of positive specimens (%)677 (1.3%)136,829 (3.7%)
Positive specimens by type
Influenza A628 (92.8%)134,464 (98.3%)
Influenza B49 (7.2%)2,365 (1.7%)


View Chart Data | View Full Screen Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
No. of specimens tested9,9071,115,302
No. of positive specimens5226,181
Positive specimens by type/subtype
Influenza A47 (90.4%)26,020 (99.4%)
(H1N1)pdm0912 (36.4%)75 (0.4%)
H3N221 (63.6%)20,591 (99.6%)
H3N2v04 (<0.1%)
Subtyping not performed145,350
Influenza B5 (9.6%)161 (0.6%)
Yamagata lineage01 (2.3%)
Victoria lineage043 (97.7%)
Lineage not performed5117




View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Outpatient Respiratory Illness Surveillance


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
Outpatient Respiratory Illness Visits


Nationwide during week 38, 2.2% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

During week 38, the percentage of visits for respiratory illness reported in ILINet was 9.0% among those 0-4 years, 3.5% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



* Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

View Chart Data | View Full Screen
Outpatient Respiratory Illness Activity Map


Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
Week 38
(Week ending
Sep. 24, 2022)
Week 37
(Week ending
Sep. 17, 2022)
Week 38
(Week ending
Sep. 24, 2022)
Week 37
(Week ending
Sep. 17, 2022)
Very High0043
High32138
Moderate222924
Low958573
Minimal4046520555
Insufficient Data10278266




*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Long-term Care Facility (LTCF) Surveillance


LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 38, 31 (0.2%) of 14,528 reporting LTCFs reported at least one influenza positive test among their residents.



View Chart Data | View Full Screen
Additional information about long-term care facility surveillance:
Surveillance Methods | Additional Data
Hospitalization Surveillance

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
HHS Protect Hospitalization Surveillance


Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 38, 739 patients with laboratory-confirmed influenza were admitted to the hospital.



View Chart Data | View Full Screen
Additional HHS Protect hospitalization surveillance information:
Surveillance Methods | Additional Data
Mortality Surveillance

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on September 29, 2022, 8.7% of the deaths that occurred during the week ending September 24, 2022 (week 38), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.6% for this week. Among the 2,035 PIC deaths reported for this week, 1,014 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and six listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



View Chart Data | View Full Screen
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality


Two influenza-associated pediatric deaths occurring in weeks 30 (the week ending July 30, 2022) and 33 (the week ending August 20, 2022) of the 2021-2022 season were reported to CDC during week 38. Both deaths were associated with influenza A viruses for which no subtyping was performed.

A total of 39 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive


Additional National and International Influenza Surveillance Information


FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
Additional influenza surveillance information from participating WHO member nations is available through
FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza:
Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

Europe:
The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

https://www.cdc.gov/flu/weekly/index.htm
 
Back
Top